Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
142
resultados
Última actualización
12/08/2025 [07:27:00]
Resultados 75 a 100 de 142
Resumen de: CN119857143A
The invention provides application of CD84 as a therapeutic target in preparation of drugs for preventing and treating inflammatory bowel diseases, and belongs to the technical field of biological medicines. The CD84 is applied to development, screening or preparation of drugs for preventing and/or treating inflammatory bowel diseases as a therapeutic target. According to the application, a dextran sodium sulfate (DSS)-induced inflammatory bowel disease classical animal model is taken as an experimental subject, and the anti-CD84 antibody is taken as a drug to block the biological function of CD84, so that the degree of DSS-induced mouse enteritis can be effectively relieved, the colorectal length can be recovered, and the secretion level of inflammatory factors can be reduced. Therefore, a new strategy is provided for targeted therapy of the inflammatory bowel disease by taking the CD84 as a therapeutic target.
Resumen de: CN119842979A
The invention relates to the technical field of biological nucleic acid detection, in particular to a primer combination, a detection method and a kit for detecting virulent strains and variants of infectious bursal disease viruses. The primer probe combination comprises three pairs of specific primer probes designed according to VP2 gene segments of a virulent strain, a variant 1 and a variant 2 of the infectious bursal disease virus, and the sequences of the three pairs of primers are as shown in SEQ ID NO: 1-9. The primer probe combination provided by the invention can achieve the purpose of distinguishing and detecting different strains of IBDV through fluorescent quantitative RT-PCR (Reverse Transcription-Polymerase Chain Reaction). The primer probe combination provided by the invention has the advantages of high sensitivity, strong specificity and the like, and provides a new effective detection means for rapid differential diagnosis of IBDV, epidemiological investigation and prevention and control of IBD clinically.
Resumen de: CN119837859A
The invention discloses an application of glabridin in preparation of related drugs for inhibiting epithelial-mesenchymal transition in inflammatory bowel diseases. In the epithelial-mesenchymal transformation process, epithelial cells lose cell polarity and intercellular connection, are transformed into mesenchymal cells in function and morphology, directly participate in fibroblast activation and extracellular matrix deposition and cause intestinal fibrosis, and are one of anti-fibrosis targets. According to the application of the glabrione in preparation of the medicine related to inhibition of epithelial-mesenchymal transition in the inflammatory bowel disease, provided by the invention, the expression change of epithelial cell markers Claudin-1 and E-cadherin caused by TGF-beta 1 and interstitial cell markers Vimentin, N-cadherin, Snail and alpha-SMA can be relieved, cell migration caused by TGF-beta is improved, and the epithelial-mesenchymal transition induced by TGF-beta 1 is inhibited. The research on the mechanism of action shows that by blocking a TGF-beta1/Smad2/3 signal channel and inhibiting AKT1 activation and inhibition of epithelial-mesenchymal transition, the application of the compound in inhibition of epithelial-mesenchymal transition and prevention of intestinal disease related fibrosis is prompted.
Resumen de: CN119846227A
The invention discloses a method, a system and equipment for evaluating the treatment effect of a CCDC71L inhibitor on radiation enteritis. It is found for the first time that knock-down of CCDC71L in human colorectal epithelial cells subjected to irradiation treatment can play a role in treating radioactive injury by regulating and controlling a lipid metabolism pathway and a ferroptosis pathway. On the basis, the invention provides a method, a system and equipment for evaluating the treatment effect of the CCDC71L inhibitor on the radiation enteritis for the field, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the radiation enteritis, and a clinician is guided to formulate an individualized treatment scheme for the patient.
Resumen de: US2025122569A1
The invention relates to methods of predicting a patient's responsiveness to treatment (e.g., vedolizumab treatment) for inflammatory bowel disease (IBD).
Resumen de: WO2025079348A1
It has been revealed that, from an analysis of the mechanism regarding the action of sulfasalazine which is a therapeutic drug for inflammatory bowel disease, an anti-inflammatory action occurs by increasing intracellular glutamate. As a result of a detailed analysis, it has been revealed that a glutamine synthetase inhibitor or an xCT inhibitor which increases intracellular glutamate has a therapeutic effect on inflammatory bowel disease. Further, it is considered that a compound that suppresses expression of a glutamine synthesis inhibiting enzyme or xCT also has a therapeutic effect. An xCT inhibitor or a glutamine synthetase inhibitor is useful as a prophylactic/therapeutic drug that is for inflammatory diseases, particularly inflammatory bowel disease, and that has no serious side effects such as immunosuppression.
Resumen de: EP4537847A2
Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to inflammation, such as necrotizing enterocolitis, mesenteric ischemia, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, lymphocytic colitis, Celiac disease, Behcet's disease, rheumatoid arthritis, psoriasis, and autoimmune thyroid disease.
Resumen de: CN119818682A
The invention belongs to PDIA1, and particularly relates to application of PDIA1 as a drug screening target in preparation of drugs for treating ulcerative colitis. The technical problem to be solved by the invention is to provide a new molecular target for recovery of intestinal epithelial barriers in ulcerative colitis. The expression level of PDIA1 in epithelial cells of patients with ulcerative colitis is higher than that of healthy people, and symptoms of ulcerative colitis can be effectively improved by inhibiting PDIA1. The invention provides a new thought for further researching the intestinal epithelial barrier recovery mechanism and the medical application of the PDIA1.
Resumen de: WO2025075714A1
Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.
Resumen de: WO2025076081A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: US2025114413A1
The present disclosure relates to a formulation for supporting the growth or maintenance of bacteria in the gastrointestinal tract of an animal. Provided is the use of at least one human milk oligosaccharide in combination with pre-biotics and probiotic strains of bacteria for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of beneficial bacteria in the gastrointestinal tract in context of a disease condition. Also provided is a synbiotic formulation comprising living beneficial bacteria formulated with at least one human milk oligosaccharide in combination with pre-biotics. In particular, synbiotic formulation is used for improving clinical biomarkers in diseases especially Crohn's disease.
Resumen de: WO2025076414A1
The disclosure provides methods for predicting response in a subject having IBD to anti-IL12 and/or anti-IL23-based therapies, and selecting an effective therapy.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: CN119776531A
The invention relates to application of an SNTB1 gene in occurrence and development of colorectal cancer caused by colitis and proctitis. The key effect of the SNTB1 gene in occurrence and development of colorectal cancer caused by colorectal cancer is creatively disclosed, a new perspective is provided for pathogenesis and molecular fundamental research of colorectal cancer, and development of targeted treatment strategies or prevention methods is facilitated. And secondly, the SNTB1 gene is used as a biomarker, so that effective screening of colitis cancer transformation high-risk groups can be realized, and the early diagnosis rate is improved. Besides, the SNTB1 gene expression promoter provided by the invention can be used for constructing a whole-process animal model for colorectal cancer transformation, and a powerful tool is provided for deeply researching pathogenesis of colorectal cancer and screening drugs. Meanwhile, the prepared preventive pharmaceutical composition is expected to effectively prevent transformation of colitis and proctitis cancers by inhibiting SNTB1 gene expression.
Resumen de: CN119780430A
The invention discloses an application of a response marker for treating ulcerative colitis by coprophilous fungi transplantation, and belongs to the technical field of biology, as a further optimization scheme of the invention, the coprophilous fungi comprise Streptococcus, Faecalibacteria, Weissella, Lactococcus and Rombout, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation has the advantages that the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized. As a further optimization scheme of the invention, the coprophilous bacteria further comprise Streptococcus pluviae, Bifidobacterium longum, Lactococcus garviae, Weissella parasites, Lactococcus fermentum and Lactococcus lactis, and the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae and the In the invention, the flora change before and after coprophilous fungus transplantation treatment is researched on a pati
Resumen de: US2025109209A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: US2025109210A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: CN119724354A
The invention discloses a screening method and application of an ulcerative colitis biomarker, EPHX2 can be used as a biomarker for ulcerative colitis detection, provides a new technical means for ulcerative colitis detection, diagnosis, treatment and prognosis evaluation, provides a new direction for research of UC pathogenesis, and provides a new application prospect. And a new possibility is provided for clinical treatment.
Resumen de: WO2025064645A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD) and to physiologically acceptable compositions of isolated bacterial strains, lysates thereof, and supernatants therefrom for use in treating IBD.
Resumen de: US2025104866A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: WO2025064813A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: CN119255775A
A defecation detection and alert system includes a sensing device mounted to an absorbent article for alerting a caregiver of the presence of solid excreta by analyzing gas expelled from the absorbent article during defecation. The system includes an elongate conduit made of a flexible material and mounted to an absorbent article. The pipeline is connected to a gas sensor arranged in the hanging device, and the gas sensor determines whether defecation occurs in the absorption product or not by detecting existence of hydrogen sulfide gas.
Resumen de: CN119685466A
The invention discloses an application of DUOX2 in identification of ileum subtype and colon subtype Crohn's disease. A group of new DUOX2-epi is analyzed and identified based on single cell transcriptome sequencing, the proportion of the cells in the Crohn disease inflammation tissue is obviously increased, and the proportion of the DUOX2-epi in the colon type Crohn disease inflammation tissue is obviously higher than that in the ileum type Crohn disease inflammation tissue; in addition, in ileum type and colon type Crohn diseases, interaction with surrounding cells is carried out through different mechanisms, so that the occurrence and development of the diseases are promoted. Therefore, based on a DUOX2-epi mediated intercellular communication network, a gene prediction module for predicting different subtypes of Crohn diseases and evaluating the treatment effect of a biological agent is developed, and based on a DUOX2 molecular network, an experimental basis and a research direction are provided for subsequent in-depth research, and a new strategy is expected to be provided for diagnosis and treatment of different subtypes of Crohn diseases.
Resumen de: CN119693421A
The invention discloses a mouse intestinal peristalsis speed detection method and device based on a fluid dense optical flow algorithm, and the method specifically comprises the steps: carrying out the dyeing imaging of a mouse intestinal tract, and shooting a mouse intestinal peristalsis video; carrying out calculation region framing on the complete mouse intestine peristalsis video, extracting an intestine region contour of the mouse, and framing a rectangular image region needing to be calculated; the method comprises the following steps: preprocessing a mouse intestine peristalsis video, filtering breathing frames frame by frame, marking frames influenced by breathing as invalid frames, and skipping in subsequent optical flow calculation; performing optical flow calculation: circularly reading every two frames of the video, and obtaining a group of optical flows after respiration influence is eliminated by using a fluid-based dense optical flow algorithm; and (n-1) groups of optical streams obtained by the n frames of videos are superposed along a time axis to obtain an optical stream index at each pixel point in the whole intestinal region so as to determine the intestinal peristalsis speed of the mouse. The mouse intestinal tract can be monitored in real time and repeatedly evaluated, and theoretical support is provided for diagnosing inflammatory bowel diseases and discovering potential therapeutic drugs.
Nº publicación: CN119666500A 21/03/2025
Solicitante:
HANGZHOU COSMOS WISDOM BIOTECH CO LTD
\u676D\u5DDE\u5E7F\u79D1\u5B89\u5FB7\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
Resumen de: CN119666500A
The invention provides a biomarker for predicting whether an individual suffers from progression-stage adenoma or not and application of the biomarker. Proteins with significantly different abundance levels in blood of patients and healthy control people at different stages in the colorectal cancer tumor process (inflammatory disease-benign polyp-progression-stage adenoma-colorectal cancer) are analyzed, and a plurality of protein markers capable of being used for progression-stage adenoma risk prediction are screened out. On one hand, a dichotomy algorithm is adopted, a model is built based on a random forest, good performance is shown in distinguishing of progression-stage adenoma and healthy control, the AUC value reaches 0.807, and high diagnostic value is achieved; a six-classification algorithm is further adopted, a model is constructed through gradient lifting, progressive-stage adenoma, early-stage colorectal cancer, benign polyp, inflammatory bowel disease, other cancers and healthy people can be effectively distinguished, the accuracy of the model is 0.78, the consistency is 0.729, the diagnosis sensitivity of the progressive-stage adenoma is 73.4%, and the specificity is 94.7%; and a new way is provided for progression stage adenoma diagnosis.
BOPI
Sede Electrónica
